Table 1.
LET and survival parameters for OE21 and KYSE450
| OE21 | LET (keV / μm) | α (Gy−1) | β (Gy−2) | α/β (Gy) | D10 (Gy) | D37 (Gy) | RBE10 | RBE37 |
| 6MV X-ray | 2.36 | 0.06 ± 0.03 | 0.06 ± 0.01 | 0.88 | 5.63 ± 0.14 | 3.55 ± 0.13 | ||
| #1 | 2.85 | 0.17 ± 0.03 | 0.05 ± 0.01 | 3.23 | 5.36 ± 0.29 | 3.07 ± 0.05 | 1.06 ± 0.04 | 1.16 ± 0.03 |
| #2 | 4.65 | 0.23 ± 0.03 | 0.05 ± 0.01 | 4.37 | 4.80 ± 0.10 | 2.68 ± 0.08 | 1.17 ± 0.02 | 1.33 ± 0.04 |
| #3 | 5.64 | 0.16 ± 0.07 | 0.07 ± 0.02 | 2.16 | 4.63 ± 0.15 | 2.71 ± 0.06 | 1.22 ± 0.03 | 1.31 ± 0.03 |
| #4 | 8.14 | 0.24 ± 0.05 | 0.06 ± 0.01 | 4.05 | 4.56 ± 0.11 | 2.57 ± 0.16 | 1.24 ± 0.03 | 1.40 ± 0.06 |
| KYSE450 | LET (keV / μm) | α | β | α/β | D10 | D37 | RBE10 | RBE37 |
| 6MV X-ray | 2.36 | 0.06 ± 0.02 | 0.02 ± 0.00 | 3.40 | 9.55 ± 0.30 | 5.81 ± 0.30 | ||
| #1 | 2.85 | 0.05 ± 0.03 | 0.02 ± 0.00 | 2.38 | 9.25 ± 0.13 | 5.70 ± 0.16 | 1.03 ± 0.02 | 1.02 ± 0.04 |
| #2 | 4.65 | 0.08 ± 0.04 | 0.02 ± 0.01 | 3.81 | 9.06 ± 0.20 | 5.35 ± 0.22 | 1.06 ± 0.02 | 1.09 ± 0.04 |
| #3 | 5.64 | 0.07 ± 0.03 | 0.03 ± 0.01 | 2.64 | 7.98 ± 0.18 | 4.82 ± 0.07 | 1.20 ± 0.03 | 1.21 ± 0.04 |
| #4 | 8.14 | 0.09 ± 0.03 | 0.03 ± 0.00 | 3.11 | 7.68 ± 0.03 | 4.61 ± 0.15 | 1.24 ± 0.02 | 1.27 ± 0.05 |
LET linear energy transfer, D 10 dose required to reduce the fraction of surviving cells to 10%, D 37 dose required to reduce the fraction of surviving cells to 37%, RBE 10 relative biological effectiveness at the survival dose of 10%, RBE 37 relative biological effectiveness at the survival dose of 37%